GB2094750A - Encapsulation and release of core material - Google Patents

Encapsulation and release of core material Download PDF

Info

Publication number
GB2094750A
GB2094750A GB8207308A GB8207308A GB2094750A GB 2094750 A GB2094750 A GB 2094750A GB 8207308 A GB8207308 A GB 8207308A GB 8207308 A GB8207308 A GB 8207308A GB 2094750 A GB2094750 A GB 2094750A
Authority
GB
United Kingdom
Prior art keywords
polymer
solution
process according
stripping
capsules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB8207308A
Other versions
GB2094750B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Damon Corp
Original Assignee
Damon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Damon Corp filed Critical Damon Corp
Publication of GB2094750A publication Critical patent/GB2094750A/en
Application granted granted Critical
Publication of GB2094750B publication Critical patent/GB2094750B/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02Making microcapsules or microballoons
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02Making microcapsules or microballoons
    • B01J13/20After-treatment of capsule walls, e.g. hardening
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012Cell encapsulation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/70Polysaccharides
    • C12N2533/74Alginate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Abstract

A process for microencapsulating a core material and subsequently releasing the core material by selectively disrupting the membranes of the microcapsules involves the formation of a water-insoluble semipermeable membrane, e.g., around a droplet, through formation of multiple ionic salt bonds between a polyionic polymer in the droplet and a crosslinking polyionic polymer which possesses multiple ionic groups of opposite charge. The membrane is disrupted by exposing it to a solution of competing crosslinking multivalent (preferably di or trivalent) ions and to a solution of a competing polyionic polymer of the same charge as the polymer in the original droplet. The two competing reagents may be used in admixture. The competing reagents convert the membranes into a water-dispersible or soluble gel from which is then completely disrupted by exposure to a sequestering agent.

Description

SPECIFICATION Improvements relating to encapsulation This invention relates to improvements relating to encapsulation and more particularly to a method of encapsulation which is reversible, that is, a method which may be used to encapsulate a liquid or a solid material and thereafter to release the material by selectively disrupting the capsule membranes. An important use of the invention is for the microencapsulation of living cells which may subsequently be released from within the enclosing capsules without damage.
Our U.K. patent application No. 8008971, publication No. GB 2 046 209A discloses a microencapsulation technique which can eb used to encapsulate essentially any solid or liquid material within semipermeable or substantially impermeable capsule membranes. An outstanding advantage of the technique is that the conditions under which the capsule membranes are formed involve no toxic or denaturing reagents, extremes of temperature, or other conditions which might damage living cells, The technique of that application is accordingly wellsuited for the production of microencapsulated living materials which remain viable and in a healthy state.Because the technique allows a degree of control of the permeability of the membrane, it is now possible to microencapsulate cell cultures of procaryotic eukarotic, or other origin such that cells of the culture are protected from contaminating bacteria, high molecular weight immunoglobulins, and other potentially deleterious factors, and remain confined within a microenvironment well-suited for their continuing viability and ongoing metabolic functions. If the microcapsules are suspended in a conventional culture medium sufficient to support growth of the living cells involved, the microencapsulated cells are free to ingest substances needed for metabolism which diffuse through the membrane and to excrete their metabolic products through the capsule membrane into the surrounding medium.
An object of the present invention is to provide a process whereby capsules can be formed and thereafter readily disrupted selectively to release their contents without damaging the contents, however.
Desirably, disruption is possible without damaging proximate living tissue. Our process is applicable to the encapsulation and subsequent release of finely divided solids, liquids and solutions including cultures of living cells.
According to the present invention, there is provided a process for selectively disrupting a permeable membrane comprising a matrix of a first polymer having multiple cationic moieties and a second polymer having multiple anionic moieties and a first charge density, the two polymers being connected by salt bridges between said anionic and cationic moieties, and the process comprising the steps of: A. exposing the membrane to a solution of cations and a stripping polymer having plural anionic moieties, said stripping polymer having sufficient charge to disrupt said salt bridges; B. allowing said cations in solution to compete with said first polymer for anionic sites on said second polymer, and said stripping polymer to compete with said second polymer for cationic sites on said first polymer; and C. sequestering cations associated with said second polymer after step B.
Also according to the present invention, there is provided encapsulated matter, wherein the capsules thereof comprise two polymers having multiple ionic moieties of opposite charge and connected by salt bridges between their respective oppositely charged ionic moieties, and a kit of reagents for releasing the said matter by disrupting the capsules, the kit including a solution of cations for competing with one polymer for anionic sites on the other polymer, a solution of a stripping polymer for disrupting the salt bridges and for competing with the said other polymer for cationic sites on the said one polymer, and a sequestering agent for completing disruption of the weakened, water-dispersible capsule material resulting from the action of the cation solution and the stripping polymer.
The following description is now given by way of example of the invention.
The present invention is concerned with a method of selectively disrupting capsule membranes synthesized during a microencapsulation procedure as set forth in GB 2046 209A without any significant or detectable damage to the encapsulated core material. The present process is practiced on membranes comprising a water-insoluble matrix formed from at least two water-soluble components. One component is a polymer which includes multiple cationic moieties (polycationic polymer, e.g. polyethylene amine). The second component is a polymer having multiple anionic moieties (polyanionic polymer, e.g.
sodium alginate gum). The two components are connected by salt-bridges between the anionic and cationic moieties to form the matrix.
The present process involves exposing membranes of the type set forth above to a solution of cations, preferably, monatomic or very low moleculay weight multivalent cations, and to a solution of a stripping polymer having plural anionic moieties.
Preferably, these solutions are mixed together, although they could be applied sequentially. The anionic charge of the polymer should be sufficient to disrupt the salt bridges and should preferably be equal to or greater than the charge density of the polyanionic polymer of the membrane. In the preferred practice, the mixed solution is contacted with the capsules to allow the cations, e.g., calcium or aluminum, to compete against the polycationic polymer in the capsule membrane for anionic sites on the polyanionic polymer. Simultaneously, the stripping polymer having plural anionic moieties competes with the polyanionic polymer for cationic sites on the polymer chains. This results in "softening" or "unzipping" of the capsule membranes.To complete the disruption, the capsules are washed and then exposed to a sequestering agent to remove cations associated with the polyanionic polymer.
The preferred sequestering agents are chelating agents such as citrate ions or EDTA ions. If, as in an important embodiment, the capsules contain viable cells, it is preferred to mix the sequestering agent with an isotonic saline solution.
The currently preferred cation solution contains calcium. Examples of the stripping polymer having plural anionic groups used in the mixed solution include polysulfonic acids or preferably their salts, either natural or synthetic. Outstanding results have been obtained usng heparin, a natural polymer containing plural sulfonate groups. Stripping poiym- ers containing polyphosphoric or polyacrylic acid salt moieties may also be used. The currently preferred sequestering agent is sodium citrate.
The invention also contemplates a method of encapsulating viable cells within a protective environment and subsequently releasing the cells.
Thus, the invention provides what may be described as a package which maintains living cell cultures of whatever origin in a sterile, stabilizing environment in which they can undergo normal metabolism and even mitosis and from which they subsequently can be released.
The selective membrane disruption process is practiced on membranes consisting of a salt bridgebonded matrix of a polycationic polymer and a polyanionic polymer. Usually, the membranes will have a spheroidal form defining an enclosed interior containing an encapsulated substance. However, the process may also be practiced on membranes of this type which take otherthan spheroidal form.
Although essentially any material (compatible with aqueous environments) in liquid or solid form can be encapsulated and subsequently released without damage by the present process, its most notable utility, as presently contemplated, lies in its ability to encapsulate and subsequently release living systems such as cell cultures. Accordingly, the description which follows will be primarily confined to a discussion of the encapsulation and release of cells. Those skilled in the art will be able to adapt the process without difficulty to the encapsulation of less fragile materials.
Encapsulation The tissue or cells to be encapsulated are suspended in an aqueous medium suitable for maintenance and for supporting the ongoing metabolic processes of the particular cell type involved. Media suitable for this purpose are well known to those skilled in the art and often are available commercially. The average diameter of the cell mass or other material to be encapsulated can vary widely between a few microns to a millimeter or more.
Mammalian islets of Langerhans, for examples, are typically 50 to 200 microns in diameter. Tissue fragments and individual cells such a fibroblasts, leukocytes, lymphoblastoids, pancreatic beta, alpha or delta cells, islet of Langerhans, hepatocytes, or the cells of othertissue may be encapsulated as desired. Also, microorganisms may be encapsulated including those which have been genetically modified by recombinant DNA or other techniques.
The ongoing viability of such living matter is dependent, inter alia, on the availability of required nutrients, oxygen transfer, absence of toxic subst- ances in the medium, and the pH of the medium.
Until recently, it has not been possible to maintain such living matter in a physiologically compatible environment while simultaneously encapsulating.
The problem has been that the conditions required for membrane formation have been lethal or harmful to the tissue, and prior to the invention disclosed in GB 2 046 209A no method of membrane formation which allowed tissue to survive in a healthy state had been forthcoming.
However, it has been discovered that certain water-soluble substances which are physiologically compatible with living tissue and can be rendered water-insoluble to form a shape-retaining, coherent mass, can be used to form a "temporary capsule" or protective barrier layer about individual cells, groups of cells, or tissues. Such a substance is added, typically at a concentration on the order of 1-2 weight percent, to the tissue culture medium. The solution is then formed into droplets containing tissue together with its maintenance or growth medium and is immediately rendered waterinsoluble and gelled, at least in a surface layer.
Thereafter, the shape-retaining temporary capsules are provided with a more permanent membrane which, in accordance with this invention, may be subsequently selectively disrupted to release the encapsulated tissue without damage. Where the material used to form the temporary capsules permits, the capsule interior may be reliquified after formation of the permanent membrane. This is done by re-establishing the conditions in the medium at which the material is soluble.
The material used to form the temporary capsules may be any non-toxic, water-soluble material which, by a change in the surrounding ionic environment or concentration, can be converted to a shape-retaining mass. The material also comprises plural, easily ionized anionic moieties, e.g., carboxyl groups, which can react by salt-bond formation with polymers containing plural cationic groups. As will be explained below, this type of material enables the deposition of the permanent membrane of a selected permeability (from substantially nonporous to a level of several hundred thousand daltons, i.e. having pores large enough to pass molcules having molecular weights of this level).
The presently preferred polyanionic materials for forming the temporary capsule are acidic, watersoluble, natural or synthetic polysaccharide gums.
Many such materials are commercially available.
They are typically extracted from vegetable matter and are often used as additives to various foods.
Sodium alginate is the presently preferred anionic polymer. Alginate in the molecular weight range of 150,000+ daltons may be used, but because of its molecular dimensions will usually be unable to permeate the finally formed capsule membranes. To make capsules without trapped liquid alignate, lower molecular weight alginate, e.g., 40,000-80,000 daltons can be used. In the finished capsule, the alginate can then be more easily removed from the intracapsularvolume by diffusion through a membrane of sufficient porosity. Other useable polyanionic gums include acidic fractions of guar gum, carageenan, pectin, tragacanth gum, or xanthan gum.
These materials comprise glycoside-linked saccharide chains. Their free acid groups are often present in the alkali metal ion form, e.g., sodium form. If a multivalent ion such as calcium, strontium, or aluminum is exchanged for the alkali metal ion, the liquid, water-soluble polysaccharide molecules are "cross-linked" to form a water-insoluble, shaperetaining gel which can be resolublized on removal of the ions by ion exchange or via a suquestering agent. While essentially any multivalent ion which can form a salt with the acidic gum is operable, it is preferred that physiologically compatible ions, e.g., calcium, be employed. This tends to preserve the tissue in the living state. Other multivalent cations can be used for less fragile material. Magnesium ions are ineffective in gelling sodium amiginate, however.
A typical solution composition comprises equal volumes of a cell suspension in its medium and a one to two percent solution of gum in physiological saline. When employing sodium alginate, a 1.2 to 1.6 percent solution has been used with success.
In the next step of the encapsulation process, the gum solution containing the tissue is formed into droplets of a desired size sufficient to envelop the cells to be encapsulated. Thereafter, the droplets are immediately gelled to form shape-retaining spherical or spheroidal masses. The drop formation may be conducted by known techniques.
Atube containing an aqueous solution of multivalent cations, e.g., 1.5% CaCI2 solution, is fitted with a stopper which holds a drop forming apparatus. The apparatus comprises a housing having an upper air intake nozzle and an elongate hollow body friction fitted into the stopper. A 10 cc syringe equipped with a stepping pump is mounted atop the housing with, e.g., a 0.01 inch (0.25 mm) I.D. Teflon coated needle passing through the length of the housing. The interior of the housing is designed such that the tip of the needle is subjected to a constant laminar air flow which acts as an air knife. In use, with the syringe full of solution containing the material to be encapsulated, the stepping pump is actuated to incrementally force droplets of solution from the tip of the needle.Each drop is "cut off" by the air stream and falls approximately 2.5 cm into the CaCI2 solution where it is immediately gelled by absorption of calcium ions. The distance between the tip of the needle and the surface of the CaCI2 solution is great enough, in this instance, to allow the sodium alginatelcell suspension to assume the most physically favorable shape; a sphere (maximum volume for minimum surface area). Air swithin the tube bleeds through an opening in the stopper. This results in "cross-linking" of the gel and in the formation of a high viscosity, shape-retaining protective temporary capsule containing the suspended tissue and its medium. The capsules collect in the solution as a separate phase and are separated by aspiration.
In the next step of the process, a membrane is deposited about the surface of the temporary capsules by cross-linking surface layers. This is done by subjecting the temporary capsules comprising polyanion to an aqueous solution of a polymer containing cationic groups reactive with anionic functionalities in the polyanionic polymer. Polymers containing reactive cationic groups such as free amine groups or combinations of amine and imine groups are preferred. In this situation, the polysaccharide gum is crosslinked by interaction (salt bond formation) between the carboxyl groups and the amine or imine groups of the polycationic polymer. Advantageously, permeability can be controlled within limits by selecting the molecular weight of the cross-linking polymer used and by varying exposure time and the concentration of polymer in solution.A solution of polymer having a low molecular weight, in a given time period, will penetrate further into the temporary capsules than will a high molecularweightpolymer.
The degree of penetration of the cross-linker has been correlated with the resulting permeability. In general, the higher the molecular weight and the less penetration, the larger the pore size. Longer exposures and more concentrated polymer solutions tend to decrease the resulting membrane's upper limit of permeability. However, the average molecular weight of the polymer is the dominant determinant. Broadly, polymers within the molecular weight range of 10,000 to 100,000 daltons or greater may be used, depending on the duration of the reaction, the concentration of the polymer solution, and the degree of permeability desired.
One successful set of reaction conditions, using polylysine of average molecular weight of about 35,000 daltons, involved reaction for three minutes, with stirring, of a physiological saline solution containing 0.0167 percent polylysine. This results in membranes having an upper limit of permeability of about 100,000 daltons. Generally, higher molecular weight materials form membrane which are more difficult to subsequently disrupt as compared with lower molecular weight materials. The charge density of the crosslinking polycationic polymer also affects the pore size and ease of membrane disruption. Generally, higher charge density materials form less porous membranes which are more difficult to disrupt. Optimal reaction conditions suitable for controlling permeability in a given system can readily be determined empirically in view of the foregoing guidelines.
Examples of suitable cross-linking polymers include proteins and polypetides, either natural or synthetic, having free amino or combinations of amino and imino groups, polyethyleneamines, polyethyleneimines, and polyvinylamines. Polylysine, in both the D and Lforms, has been used with success. Proteins such a polyarginine, polycitrulline, or polyornithine are also operable. Polymers in the higher range of positive charge density (e.g., polyvinylamine) vigorously adhere to the anionic groups of the polyanionic molecules and are more difficult to disrupt.
At this point in the encapsulation, capsules may be collected which comprise a "permanent" semipermeable membrane surrounding a gelled solution of gum, cell-type compatible culture medium, and the cells. If the object is simply to preserve the cells in a protective environment, no further steps need be done. However, if mass transfer is to be promoted within the capsules and across the membranes, it is preferred to reliquify the gel to its water-soluble form. This may be done by reestablishing the conditions under which the gum is a liquid, e.g., removing the calcium or other multifunctional cations from the gel. The medium in the capsule can be resolibilized simply by immersing the capsules in phosphate buffered saline, which contains alkali metal ions and hydrogen ions.Monovalent ions exchange with the calcium or other multifunctional ions within the gum when the capsules are immersed in the solution with stirring. Sodium citrate solutions may be used for the same purpose, and serve to sequester the divalent ions. Gum molecules having a molecular weight belowthe upper limit of permeability of the membranes may subsequently be removed from the intracapsular volume by diffusion.
Lastly, it may be desirable to treat the capsules so as to tie up free amino groups of the like which might otherwise impart to the capsuls a tendency to clump.
This can be done, for example, by immersing the capsules in a dilute solution of sodium alginate.
From the foregoing it will be apparent that no harsh reagents, extremes of temperature, or other conditions deleterious to the health and viability of the cells need be used in the membrane formation process. Thus, even very sensitive cells such as mammalian hepatocytes, leukocytes, fibroblasts, lymphoblasts, and cells from various endocrine tissues may be encapsulated without difficulty. Of course, cells of microbial origin such as yeasts, molds, and bacteria which are better adapted to survive in hostle environments, as well as inert reagents, solids, or biologically active materials may also be encapsulated without damage.
Encapsulated cells of the type described above may be suspended in maintenance medium or growth medium for storage or culture and will remain free of bacterial infection. If suspended in growth medium, cells which undergo mitosis in vitro will do so within the capsules. Normal in vitro metabolism continues provided the factors needed for metabolic processes are of sufficiently low molecular weight that they can penetrate the capsule membrane, or are encapsulated together with the cells. Metabolic products of the cells (if of a moleculay weight below the upper limit of permeability) penetrate the membrane and collect in the medium.
The cells in encapsulated form may be stored, shipped, or cultured as desired, and may be released from their protective environment without damage by means of the following process of selectively disrupting the membranes.
Disruption of Membrane In accordance with the invention the encapsulated material may be released by a two-step process involving commercially available reagents having properties which do not adversely affect the encapsulated cells.
First, the capsules are separated from their suspending medium, washed thoroughly to remove any contaminants and then dispersed with agitation, in a solution of cations such as calcium ions or other monatomic (low molecular weight, multivalent cation) and then in a stripping polymer having plural anionic moieties such as polysulfonic acid groups.
The two solutions can, preferably, be mixed together.
Polymers containing polyphosphoric or polyacrylic acid moieties may also be used. Heparin, a natural sulfonated polysaccharide, is peferred for disrupting membranes containing cells. The anionic charge of the stripping polymer used must be sufficient to disrupt the salt bridges. Thus the anionic charge density may be equal to or preferably greater than the charge density of the interior polyanionic polymer (e.g., the gum) originally employed to form the membranes. The molecular weight of the stripping polymer should be at least comparable to and preferably greater than the molecular weight of the interior polycationic polymer used in forming the membrane.Within the suspension, the calcium ions compete with the interior polycationic polymer comprising the membrane for anionic sites on the polyanionic polymers Simultaneously, the stripping polymer dissolved in the solution competes with the polyanionic gum in the membrane for cationic sites on the polycationic polymer. This results in a water-dispersible or preferably water-soluble complex of, e.g., polylysine and the polyanionic polymer, and in association of the cations with gel molecules.
This step renders the membrane susceptible to subsequent exposure to a sequestering agent which completes the disruption process by taking up di or trivalent ions from the gel. Typically, capsule membrane debris, if any, which remains in the medium can be separated easily from the cells.
The currently preferred solution for the first stage of the selective disruption process comprises 1.1% calcium cloride (w/v) and between 500 to 1,500 units of heparin per milliliter of solution. A volume of microcapsules is added to this solution sufficient to constitute between about 20% and 30% of the total volume of suspension. Calcium chloride and heparin are preferred when disrupting membranes of cellcontaining capsules since both reagents are physiologically compatible with most cells and minimize the possibility of cell damage. Mixtures of aluminum salts or other multivalent cations (but not Mg++ ions) may also be used together with the polysulfonic or other acid salt of the type set forth above.
In general, the concentration of the ions and anionic polymer in the solution used in this step may vary widely. Optimum concentrations may be readily determined empirically. The lowest operable concentration for a particular batch of encapsulated cells is preferred.
The currently preferred sequestering agent for performing the selective disruption is sodium citrate, although other alkali metal citrate salts and alkali metal EDTA may also be used. When sodium citrate is employed, the optimum concentration is on the order of 55 mM. Where the capsule membranes being disrupted contain viable tissue, it is preferred that the citrate be dissolved in isotonic saline so as to minimize cell damage.
The invention will be further understood from the following non-limiting examples.
Capsule Formation Example 1: Encapsulation of Pancreatic Tissue Islets of Langerhans are obtained from rat pancreas and added to a complete tissue culture (CMRL1969 Connaught Laboratories, Toronto, Canada) at a concentration of approximately 1 103 islets per milliliter. The tissue culture contains all nutrients needed for continued viability of the islets as well as the amino acids employed by the cells for making hormones. Four-tenths of a milliliter of an islet suspension containing approximately 103 islets per milliliter is then added to a one-half milliliter volume of 1.2 percent sodium alginate (Sigma Chemical Company) in physiological saline.
Next, a 1.5 percent calcium chloride solution is used to gel droplets on the order of 300-400 microns in diameter. Afterthe supernatant solution is removed by aspiration, the gelled droplets are transferred to a beaker containing 15 ml of a solution comprising one part of a 2% 2 (cyclohexylamino) ethane sulfonic acid buffer solution in 0.6% NaCI (isotonic, pH=8.2) diluted with 20 parts 1% CaCI2.
After a 3 minute immersion, the capsules are washed twice in 1% CaCI2.
The capsules are then transferred to a 32 ml solution comprising 1/80 of one percent polylysine (average MW 35,000 amu) in physiological saline.
After 3 minutes, the polylysine solution is decanted.
The capsules are washed with 1% CaCI2, and optionally resuspended for 3 minutes in a solution of polyethyleneimine (MW 40,000-60,000) produced by diluting a stock 3.3% polyethyleneimine solution in morpholino propane sulfonic acid buffer (0.2M, pH=6) with sufficient 1% Cacti2 to result in a final polymer concentration of 0.12%. The resulting capsules, having "permanent" semipermeable membranes, are then washed twice with 1% CaCI2, twice with physiological saline, and mixed with 10 ml of 0.12 percent aliginic acid solution.
The capsules resist clumping, and many can be seen to contain islets of Langerhans. Gel on the interior of the capsules is reliquified by immersing the capsules in a mixture of saline and citrate buffer (pH-7.4) for 5 minutes. Lastly, the capsules are suspended in CMLR-69 medium.
Underthe microscope, these capsules are observed to comprise thin membrane which encircles an islet within which individual cells can be seen. Molecules having a molecularweight up to about one-hundred thousand can transverse the membranes. This allows oxygen, amino acids, nutrients, and plasma components used in culture media (e.g., lower molecular weight fetal calf serum components) to reach the islet and allows insulin to be excreted.
Example 2: Encapsulation of Hepatocytes The procedure of example 1 is repeated except that 0.5 ml of a liver cell suspension containing about 105 cells per milliter is used in place of the 0.4 ml islet suspension. The ongoing viability of the liver cells has been demonstrated by the dye exclusion technique (trypan blue exclusion) and by their observed ability to continuously produce urea. It is known that liver tissue, in vitro, can ingest toxins from its environment. Accordingly, toxins of a molecular weight low enough to pass through the semipermeable membranes are detoxified by the cells.
Example 3: Activated Charcoal Encapsulation The procedure of example 1 is repeated except that particulate activated charcoal is suspended directly in the sodium alginate solution, the half milliliter of tissue suspension is omitted, and polylysine of of an average molecular weight of 35,000 is used as a cross-linker. As long as the charcoal particles are smaller than the smallest inside diameter of the capillary used to produce the droplets, charcoal of high surface area surrounded by a semipermeable membrane results. These effectively prohibit the escape of charcoal chips or dust, yet can be used to absorb materials of any pre-selected molecular weight range from fluid passed through the capsules.
Example 4: Encapsulation of Human Fibroblasts Human fibroblasts obtained by treating human foreskin tissue with trypsin and EDTA for 5 minutes at 37"C in a known manner are suspended in a complete growth medium (CMLR 1969, Connaught Laboratories) supplemented with 40% (v/v? purified fetal calf serum, 0.8% sodium alginate (Sigma) and 200 mg/ml purified calf skin collagen. The density of the cell suspension is about 1.5 x 107 cells/ml.
Temporary alginate capsules are formed as set forth above. Semipermeable membranes are deposited in surface layers of the capsules by suspending them in a 0.005% (won) aqueous solution of poly L lysine, (MW 43,000 daltons) for 3 minutes.
The resulting capsules are suspended in CMLR1969 supplemented with 10% fetal calf serum. The foregoing steps are all conducted at 37"C. After incubation at the same temperature, the capsules, if exained under the microscope, will be found to contain fibroblasts which have undergone mitosis and display three-dimensional fibroblastic morphol ogywithin the microcapsules.
Selective Disruption ofthe Membranes Example 5 Microcapsules from any of examples 1-4 may be treated as follows in order to selectively disrupt the capsule membranes without damage to the encapsulated core material.
10 ml portions of microcapsule suspensions containing about 500-5000 capsules per ml are allowed to settle and the suspension medium is aspirated off.
The capsules are washed twice with saline. The washed capsules are then mixed with a 3.0 ml aliquot of saline containing heparin in various concentrations as set forth below and 1.1% (w/v) CaCI2. Capsules having alginate enclosed therewith is, on completion of this step, display a gelled, shape-retaining interior core. The suspension is agitated at 370C for 10 minutes, after which the capsules are allowed to settle, the supernatent is aspirated off, and the capsules are washed twice with 3.0 ml of 0.1 so NaCI. After aspiration of the secmond wash solution, the capsules are mixed with 2.0 ml of a mixed solution comprising equal volumes of 110 mM sodium citrate and 0.15 M NaCI (pH=7.4).
Capsule membranes which had been treated with 1,000 units/ml heparin and vortexed in the NaCI NaCitrate solution for 1 minute were completely disintegrated. The same result is achieved with capsules treated with 2,000 units/ml heparin for 2 minutes, followed by 15-30 seconds of hand vortexing. Lower concentrations of heparin are preferred as the possibility of cell damage is decreased.
After dissolution of the membranes any membrane debris may be removed by aspiration and washing. After the released cells are resuspended in culture medium, they may be tested by the tryptan blue dye exclusion technique and will be found to be in a healthy, viable condition, with relatively few cells exhibiting dye uptake.
Example 6 Capsules produced in accordance with example 3 are treated, after washing, with a 3.0 ml solution containing 1,000 units/ml heparin and 1.0% AlCI3 for 6 minutes with agitation. After aspiration of the supernatant, the core material is released by vortexing the capsules with a 0.1M solution of sodium citrate for 30-90 seconds.
Example 7 The procedure of example 6 is repeated except that 0.10M EDTA (sodium form) at a pH of 7.0 is used in place of the sodium citrate, resulting in rapid disruption of the capsule membranes.
Example 8 Capsules produced in accordance with example 3 are treated, after washing, with a 3.0 ml aqueous solution containing 10 mg/ml of polyvinyl sulfate (mw approximately 50,000 daltons) and 1% CaCI2.
Post treatment with 0.10M sodium citrate results in essentially complete dissolution of the capsules.

Claims (16)

1. A process for selectively disrupting a permeable membrane comprising a matrix of a first polymer having multiple cationic moieties and a second polymer having multiple anionic moieties and a first charge density, the two polymers being connected by salt bridges between said anionic and cationic moieties and the process comprising the steps of: A. exposing the membrane to a solution of cations and a stripping polymer having plural anionic moieties, said stripping polymer having sufficient charge to disrupt said salt bridges.
B. allowing said cations in solution to compete with said first polymer for anionic sites on said second polymer, and said stripping polymer to compete with said second polymer for cationic sites on said first polymer; and C. sequestering cations associated with said second polymer after step B.
2. The process according to claim 1, wherein sequestering step (C) is effected by exposing the membranes to a solution containing a chelating agent.
3. The process according to claim 2, wherein the chelating agent is selected from citrate ions and EDTA ions.
4. The process according to claim 1,2 or3 wherein the first polymer comprises multiple amino groups.
5. The process according to claim 4, wherein the second polymer comprises an acidic, water-soluble gum.
6. The process according to claim 5, wherein the second polymer comprises an alginate.
7. The process according to any preceding claim, wherein the stripping polymer comprises heparin and the said cations in solution comprise Ca++.
8. The process according to any preceding claim, wherein the stripping polymer is selected from polysulfonic acids or salts thereof, polyphosphoric acids or salts thereof; and mixtures of the foregoing.
9. The process according to any preceding claim, wherein the stripping polymer has plural anionic moieties having a charge density greater than the said first charge density.
10. The process according to claim 1, wherein the membrane defines a microcapsule containing one or more living cells.
11. The process according to claim 10, wherein the first polymer comprises a protein, the watersoluble gum comprises sodium alginate, the said cations in solution comprise calcium, and the stripping polymer having plural anionic moieties comprises heparin.
12. The process according to claim 11, wherein the sequestering step is effected with a citrate dissolved in a solution physiologically compatible with said cell(s).
13. The process according to claim 1, wherein the first polymer is selected from (a) proteins comprising plural amino acid units having free amino groups; (b) proteins comprising plural amino acid units having free imino groups; (c) polypeptides comprising plural amino acid units having free amino groups; (d) polypeptides comprising plural amino acid units having free imino groups; (e) polyvinyl amines; (f) polyethyleneimines; (g) polyethyleneamines; and mixtures of two or more of the foregoing.
14. Encapsulated matter, wherein the capsules thereof comprise two polymers having multiple ionic moieties of opposite charge and connected by salt bridges between their respective oppositely charged ionic moieties, and a kit of reagents for releasing the said matter by disrupting the capsules, the kit including a solution of cations for competing with one polymer for anionic sites on the other polymer, a solution of a stripping polymer for disrupting the salt bridges and for competing with the said other polymer for cationic sites on the said one polymer, and sequestering agent for completing disruption of the weakened, water-dispersible capsule material resulting from the action of the cation solution and the stripping polymer.
15. A process according to claim 1 andsubstan- tially as herein described by way of example.
16. Encapsulated matter and a reagent kit according to claim 14 and substantially as herein described by way of example.
GB8207308A 1981-03-13 1982-03-12 Encapsulation and release of core material Expired GB2094750B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24358481A 1981-03-13 1981-03-13

Publications (2)

Publication Number Publication Date
GB2094750A true GB2094750A (en) 1982-09-22
GB2094750B GB2094750B (en) 1984-08-22

Family

ID=22919328

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8207308A Expired GB2094750B (en) 1981-03-13 1982-03-12 Encapsulation and release of core material

Country Status (11)

Country Link
JP (1) JPS57197031A (en)
BE (1) BE892477A (en)
CA (1) CA1184518A (en)
CH (1) CH651579A5 (en)
DE (1) DE3209045C2 (en)
DK (1) DK112382A (en)
FR (1) FR2501528A1 (en)
GB (1) GB2094750B (en)
IT (1) IT1150681B (en)
NO (1) NO158284C (en)
SE (1) SE454181B (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2135954A (en) * 1980-11-14 1984-09-12 Akad Wissenschaften Ddr Microcapsules and process for the production thereof
FR2544330A1 (en) * 1983-04-15 1984-10-19 Damon Biotech Inc PROCESS, BY ENCAPSULATION AND LYSE OF CELL MEMBRANE, RECOVERY AND PURIFICATION OF A SUBSTANCE DEVELOPED BUT NOT EXCRETED BY CELLS
EP0127713A2 (en) * 1983-06-01 1984-12-12 Connaught Laboratories Limited Microencapsulation of living tissue and cells
EP0127989A2 (en) * 1983-06-01 1984-12-12 Connaught Laboratories Limited Microencapsulation of living tissue and cells
FR2559502A1 (en) * 1984-02-13 1985-08-16 Damon Biotech Inc PROCESS FOR ENCAPSULATION, IN PARTICULAR CELLS, IN SEMI-PERMEABLE MEMBRANES
EP0152898A2 (en) * 1984-02-15 1985-08-28 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system(
EP0161640A2 (en) * 1984-05-14 1985-11-21 Merck & Co. Inc. Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivo
EP0188309A2 (en) * 1985-01-03 1986-07-23 Connaught Laboratories Limited Microencapsulation of living cells
EP0213908A2 (en) * 1985-08-26 1987-03-11 Hana Biologics, Inc. Transplantable artificial tissue and process
EP0245986A2 (en) * 1986-04-28 1987-11-19 Rohm And Haas Company Immobilization of nonanchorage-dependent cells
EP0376605A1 (en) * 1988-12-22 1990-07-04 The Mead Corporation Method for forming microcapsules
WO1993003710A1 (en) * 1991-08-20 1993-03-04 University Of Leicester A method of making biocompatible capsules containing cells
US5798113A (en) * 1991-04-25 1998-08-25 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5800829A (en) * 1991-04-25 1998-09-01 Brown University Research Foundation Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core
EP1151756A1 (en) * 1999-12-08 2001-11-07 Dmitry Vladimirovich Zybin Application of polyacrylamide gel for forming a capsule in the tissue of a mammal organism, method for cultivating cells and method for therapy of oncological diseases and the diabetes mellitus
US11103585B2 (en) 2014-05-09 2021-08-31 Austrianova Singapore Pte Ltd. Use of a polyanionic composition
CN114504561A (en) * 2022-03-01 2022-05-17 陕西科技大学 Water-based coating method for preparing drug osmotic pump preparation

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO163060C (en) * 1981-03-13 1990-03-28 Damon Biotech Inc PROCEDURE FOR THE PREPARATION OF SUBSTANCES MADE BY LIVING CELLS PRODUCING INTERFERONES OR ANTIBODIES.
NO161446C (en) * 1981-03-13 1989-08-16 Damon Biotech Inc PROCEDURE FOR CULTING CELLS RELATED TO ANCHORING.
CA1245984A (en) * 1983-09-01 1988-12-06 Damon Biotech, Inc. Polyionic microencapsulation
JPS62166891A (en) * 1986-01-20 1987-07-23 Snow Brand Milk Prod Co Ltd Production of useful substance by cell cultivation
JPS6348039U (en) * 1986-09-12 1988-04-01
JPS6379587A (en) * 1986-09-22 1988-04-09 Saburo Senoo Base material for cultivating cell
WO2020066306A1 (en) * 2018-09-28 2020-04-02 富士フイルム株式会社 Cell structure, method for producing cell structure, method for culturing cells, and micro-flow path

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129921C (en) * 1958-12-31
FR1542881A (en) * 1966-10-10 1968-10-18 Ncr Co Process for preparing tiny polymer-based capsules
CH573212A5 (en) * 1973-06-29 1976-03-15 Feller Marc Rech Tech Et Et Sc Delayed release agricultural formulations - of herbicide or insecticide absorbed on porous carrier and coed with isolating layer
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2135954A (en) * 1980-11-14 1984-09-12 Akad Wissenschaften Ddr Microcapsules and process for the production thereof
FR2544330A1 (en) * 1983-04-15 1984-10-19 Damon Biotech Inc PROCESS, BY ENCAPSULATION AND LYSE OF CELL MEMBRANE, RECOVERY AND PURIFICATION OF A SUBSTANCE DEVELOPED BUT NOT EXCRETED BY CELLS
EP0127713A3 (en) * 1983-06-01 1986-03-26 Connaught Laboratories Limited Microencapsulation of living tissue and cells
EP0127713A2 (en) * 1983-06-01 1984-12-12 Connaught Laboratories Limited Microencapsulation of living tissue and cells
EP0127989A2 (en) * 1983-06-01 1984-12-12 Connaught Laboratories Limited Microencapsulation of living tissue and cells
EP0127989A3 (en) * 1983-06-01 1986-03-26 Connaught Laboratories Limited Microencapsulation of living tissue and cells
AU572609B2 (en) * 1984-02-13 1988-05-12 Damon Biotech Inc. Improved capsule membrane formation technique
GB2153780A (en) * 1984-02-13 1985-08-29 Damon Biotech Inc Encapsulation of core materials with semi-permeable membranes
FR2559502A1 (en) * 1984-02-13 1985-08-16 Damon Biotech Inc PROCESS FOR ENCAPSULATION, IN PARTICULAR CELLS, IN SEMI-PERMEABLE MEMBRANES
EP0152898A2 (en) * 1984-02-15 1985-08-28 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system(
EP0152898A3 (en) * 1984-02-15 1986-12-30 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system(
EP0161640A3 (en) * 1984-05-14 1987-12-02 Merck & Co. Inc. Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone dna, and a method of administering bgh in vivo
EP0161640A2 (en) * 1984-05-14 1985-11-21 Merck & Co. Inc. Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivo
EP0188309A2 (en) * 1985-01-03 1986-07-23 Connaught Laboratories Limited Microencapsulation of living cells
EP0188309A3 (en) * 1985-01-03 1987-09-02 Connaught Laboratories Limited Microencapsulation of living cells
EP0213908A2 (en) * 1985-08-26 1987-03-11 Hana Biologics, Inc. Transplantable artificial tissue and process
EP0213908A3 (en) * 1985-08-26 1989-03-22 Hana Biologics, Inc. Transplantable artificial tissue and process
EP0245986A2 (en) * 1986-04-28 1987-11-19 Rohm And Haas Company Immobilization of nonanchorage-dependent cells
EP0245986A3 (en) * 1986-04-28 1988-08-24 Rohm And Haas Company Immobilization of nonanchorage-dependent cells
EP0376605A1 (en) * 1988-12-22 1990-07-04 The Mead Corporation Method for forming microcapsules
US5874099A (en) * 1991-04-25 1999-02-23 Brown University Research Foundation Methods for making immunoisolatary implantable vehicles with a biocompatible jacket and a biocompatible matrix core
US5871767A (en) * 1991-04-25 1999-02-16 Brown University Research Foundation Methods for treatment or prevention of neurodegenerative conditions using immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core
US5798113A (en) * 1991-04-25 1998-08-25 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5800829A (en) * 1991-04-25 1998-09-01 Brown University Research Foundation Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core
US5800828A (en) * 1991-04-25 1998-09-01 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5834001A (en) * 1991-04-25 1998-11-10 Brown University Research Foundation Methods for making immunoisolatory implantable vehicles with a biocompatiable jacket and a biocompatible matrix core
US5869077A (en) * 1991-04-25 1999-02-09 Brown University Research Foundation Methods for treating diabetes by delivering insulin from biocompatible cell-containing devices
US6960351B2 (en) 1991-04-25 2005-11-01 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
WO1993003710A1 (en) * 1991-08-20 1993-03-04 University Of Leicester A method of making biocompatible capsules containing cells
US5529913A (en) * 1991-08-20 1996-06-25 University Of Leicester Method of removing protein from a water soluble gum and encapsulating cells with the gum
EP1151756A1 (en) * 1999-12-08 2001-11-07 Dmitry Vladimirovich Zybin Application of polyacrylamide gel for forming a capsule in the tissue of a mammal organism, method for cultivating cells and method for therapy of oncological diseases and the diabetes mellitus
EP1151756A4 (en) * 1999-12-08 2004-05-12 Dmitry Vladimirovich Zybin Application of polyacrylamide gel for forming a capsule in the tissue of a mammal organism, method for cultivating cells and method for therapy of oncological diseases and the diabetes mellitus
US11103585B2 (en) 2014-05-09 2021-08-31 Austrianova Singapore Pte Ltd. Use of a polyanionic composition
CN114504561A (en) * 2022-03-01 2022-05-17 陕西科技大学 Water-based coating method for preparing drug osmotic pump preparation
CN114504561B (en) * 2022-03-01 2023-08-11 陕西科技大学 Aqueous coating method for preparing drug osmotic pump preparation

Also Published As

Publication number Publication date
IT1150681B (en) 1986-12-17
FR2501528B1 (en) 1984-06-15
IT8220139A0 (en) 1982-03-12
CA1184518A (en) 1985-03-26
DE3209045A1 (en) 1982-09-30
SE8201557L (en) 1982-09-14
JPS57197031A (en) 1982-12-03
NO158284B (en) 1988-05-09
SE454181B (en) 1988-04-11
CH651579A5 (en) 1985-09-30
DE3209045C2 (en) 1986-06-19
BE892477A (en) 1982-07-01
NO158284C (en) 1988-08-17
DK112382A (en) 1982-09-14
NO820795L (en) 1982-09-14
FR2501528A1 (en) 1982-09-17
JPS6152737B2 (en) 1986-11-14
GB2094750B (en) 1984-08-22

Similar Documents

Publication Publication Date Title
US4407957A (en) Reversible microencapsulation of a core material
GB2094750A (en) Encapsulation and release of core material
US4409331A (en) Preparation of substances with encapsulated cells
US4495288A (en) Method of culturing anchorage dependent cells
CA1172961A (en) Process for producing substances produced by cells
US4352883A (en) Encapsulation of biological material
US4391909A (en) Microcapsules containing viable tissue cells
US4933185A (en) System for controlled release of biologically active compounds
EP0127713B1 (en) Microencapsulation of living tissue and cells
US5693514A (en) Non-fibrogenic high mannuronate alginate coated transplants, processes for their manufacture, and methods for their use
JPS59500350A (en) Encapsulation method of biological substances using bead polymers
CA1172586A (en) Method of culturing anchorage dependent cells
JPS61189218A (en) Encapsulation
EP0641183A1 (en) Coated transplant and method for making same
JPS59205985A (en) Recovery of non-secretory substance produced from cell
GB2145992A (en) Microencapsulation of viable cells
WO1988000237A1 (en) Covalent membranes
WO1987004367A1 (en) Covalent membranes
GB2119734A (en) Encapsulated living tissue
GB2119737A (en) Encapsulation of viable tissue

Legal Events

Date Code Title Description
732 Registration of transactions, instruments or events in the register (sect. 32/1977)
PCNP Patent ceased through non-payment of renewal fee